HBOT cannot restore memories that are already lost, and the evidence that it improves ongoing memory function is emerging, not settled. The strongest data is a 2022 sham-controlled trial in post-COVID patients (Zilberman-Itskovich et al.), where 73 people showed significant gains in global cognition. A separate 2020 trial in 63 healthy adults over 64 (Hadanny et al.) found similar gains, but from a single research group awaiting independent replication. For Alzheimer’s, the human evidence remains minimal.
- Hippocampus: the brain structure that forms new episodic memories and converts short-term experiences into long-term storage.
- Cerebral hypoperfusion: reduced blood flow to brain tissue, which starves neurons of oxygen and impairs their function.
- Neuroplasticity: the brain’s ability to reorganize and form new connections between neurons.
Can HBOT Reverse Memory Loss?
No. HBOT cannot bring back memories lost to neuronal death or structural brain damage. What the research is testing is a narrower question: whether raising oxygen delivery can improve the function of the memory circuits that remain, so that ongoing memory formation and recall work better. That effect is plausible and has early support in specific populations, but it is not a way to reverse established dementia or recover erased memories.
This distinction matters because a lot of marketing blurs it. The honest framing is that HBOT is being studied as a way to support memory function where reduced blood flow is part of the problem, not as a cure for memory loss. It is one of several brain conditions being explored with HBOT, and like most of them the evidence is early.
Why Is Memory So Sensitive to Reduced Blood Flow?
The hippocampus, located in the temporal lobe, is the brain’s primary center for forming new episodic memories. It is also one of the brain regions most sensitive to reduced blood flow. Even mild, chronic cerebrovascular insufficiency, the gradual decline in blood flow tied to vascular aging, arterial stiffness, and small vessel disease, can impair hippocampal function before symptoms appear elsewhere.
HBOT improves cerebral perfusion through two mechanisms: an acute rise in plasma-dissolved oxygen reaching under-supplied tissue, and longer-term promotion of angiogenesis (new blood vessel growth) in areas of vascular insufficiency. In the Hadanny 2020 trial, perfusion MRI documented increased cerebral blood flow alongside the cognitive gains. Whether that translates into meaningful memory improvement, and in whom, is what current research is trying to establish. Blood flow also shapes mood and thinking more broadly, which is covered in our guide to HBOT for mental health.
What Does the Evidence Show for Each Cause of Memory Loss?
The evidence is not uniform. It is strongest where reduced blood flow is a clear driver (post-COVID cognitive impairment) and weakest where the disease is primarily degenerative (Alzheimer’s). The table below summarizes where each cause stands.
HBOT Evidence by Cause of Memory Loss
| Cause | Best available evidence | Realistic expectation |
|---|---|---|
| Post-COVID cognition | Sham-controlled RCT, n=73 (Zilberman-Itskovich, 2022) | Measurable cognitive gains in some patients; needs replication |
| Age-related decline | Single-group RCT, n=63 (Hadanny, 2020) | Promising but from one center; not independently confirmed |
| TBI-related | Mixed trials; systematic review (Shahid, 2025); post-concussion RCT (Boussi-Gross, 2013) | Some cognitive benefit reported; results inconsistent |
| Stroke-related | Small trials, no large confirmatory RCT | Possible benefit for perfusion-related deficits; unproven |
| Alzheimer’s disease | Small open-label series (Chen, 2020); animal models | Research-stage only; not clinical treatment |
Post-COVID Memory Problems
Long COVID has created a large group of previously healthy people with new memory problems: difficulty forming new memories, word-finding trouble, and impaired recall. Neuroimaging has found cerebral hypoperfusion in many of these patients, a direct mechanistic link to HBOT’s best-established effect. The Zilberman-Itskovich 2022 double-blind, sham-controlled RCT randomized 73 patients (37 HBOT, 36 sham) and found significant improvement in global cognition, attention, and executive function after 40 sessions. This is the most methodologically sound memory-related evidence available, and it is why post-COVID cognition is graded higher than the other causes. Our page on HBOT for long COVID brain fog covers this population in more detail.
Age-Related Memory Decline
The Hadanny 2020 randomized trial found that healthy adults over 64 who received 60 HBOT sessions improved on global cognitive function and memory-related tasks, alongside increased cerebral blood flow on imaging (n=63, p=0.0017 for global cognition). These were people with normal age-related changes, not dementia. The result is encouraging, but it comes from one research group, and the field needs independent replication before it can be considered established.
Alzheimer’s Disease
Alzheimer’s involves amyloid plaques, tau tangles, neuroinflammation, and progressive neurodegeneration, alongside vascular dysfunction that many researchers believe contributes to progression. Animal models have shown reduced amyloid burden and improved performance with HBOT. Human evidence is very limited: a 2020 open-label series (Chen et al.) reported cognitive improvement in patients with Alzheimer’s disease and amnestic mild cognitive impairment, but there are no controlled human trials. The honest assessment is that HBOT for Alzheimer’s is research-stage science, not clinical medicine. Our HBOT for dementia and HBOT for Alzheimer’s patients articles cover this carefully for families navigating these decisions.
TBI and Stroke-Related Memory Loss
Traumatic brain injury and stroke can impair memory through direct damage to the hippocampus and through disruption of the networks that support recall. A 2025 systematic review (Shahid et al.) of HBOT for neurocognitive deficits after TBI found some benefit but inconsistent results across studies, and an earlier RCT in persistent post-concussion syndrome (Boussi-Gross, 2013) reported cognitive gains years after mild TBI. The broader context is in our HBOT for brain injury and HBOT for stroke patients guides.
What Reversible Causes Should You Rule Out First?
Before pursuing HBOT for memory loss, ruling out treatable causes is essential, because many conditions that impair memory respond to cheaper, better-established treatments. These include hypothyroidism, B12 deficiency, obstructive sleep apnea, depression, medication side effects (especially polypharmacy in older adults), and poorly controlled blood pressure or blood glucose.
Obstructive sleep apnea deserves special mention. It is one of the most underdiagnosed and treatable causes of memory complaints, and repeated overnight oxygen desaturations are associated with measurable hippocampal changes over time. A sleep study is a low-cost, high-yield step that should precede any HBOT consideration in at-risk individuals. Treating the apnea with CPAP or an oral appliance often improves cognition on its own. Spending thousands on HBOT while an untreated sleep disorder drives the symptoms is the wrong sequence.
A thorough evaluation by a geriatrician, neurologist, or primary care physician should include blood work for reversible causes, a medication review, sleep assessment, and possibly neuropsychological testing before any conversation about HBOT.
What Does HBOT for Memory Loss Cost and Involve?
For nearly all memory applications, HBOT is off-label and paid out of pocket. Research protocols use 40 to 60 sessions at 1.5 to 2.0 ATA, typically five days a week, which is a significant time and financial commitment. Our HBOT cost guide and insurance guide lay out the numbers, and the session guide explains what treatment involves day to day.
If you do pursue it, combining HBOT with vascular risk factor management (controlling blood pressure, diabetes, cholesterol, and smoking) and with cognitive rehabilitation gives the best chance of benefit. HBOT may support the neurobiological substrate, but activity-dependent stimulation and control of ongoing vascular damage are what shape whether the brain can use it. For patients whose memory loss affects daily function, caregiver support for transportation, scheduling, and tracking changes is part of the realistic picture, and a caregiver’s outside observation of memory-related behavior often complements formal testing.
Can HBOT restore memories that have already been lost?
No. HBOT cannot restore memories lost to neuronal death or structural brain damage. It may improve the function of remaining memory circuits through better perfusion and neuroplasticity support, which could help ongoing memory formation and retrieval. But it does not regenerate lost memories, and any provider claiming otherwise is overstating the evidence (Hadanny, 2020; Zilberman-Itskovich, 2022).
How soon after memory problems start should HBOT be considered?
Earlier is generally more promising than later, since it may address vascular and inflammatory factors before irreversible neuronal loss. For age-related decline and mild cognitive impairment there is more to work with than in end-stage dementia, where structural changes are extensive. There is no defined window after which HBOT is pointless, but the priority sequence is always to rule out and treat reversible causes first (Hadanny, 2020).
Can imaging predict whether HBOT will help my memory?
Perfusion MRI, SPECT, or transcranial Doppler can assess cerebral blood flow. Finding documented hypoperfusion in memory-related regions provides a stronger rationale for HBOT than memory complaints without a vascular cause, which is consistent with the perfusion-linked gains seen in the trials. A consultation with a hyperbaric physician who can review your imaging and history is the appropriate starting point (Zilberman-Itskovich, 2022).
Sources
- Hadanny A, Daniel-Kotovsky M, Suzin G, et al. Cognitive enhancement of healthy older adults using hyperbaric oxygen: a randomized controlled trial. Aging (Albany NY). 2020;12(13):13740-13761. doi:10.18632/aging.103571
- Zilberman-Itskovich S, Catalogna M, Sasson E, et al. Hyperbaric oxygen therapy improves neurocognitive functions and symptoms of post-COVID condition: randomized controlled trial. Sci Rep. 2022;12(1):11252. doi:10.1038/s41598-022-15565-0
- Boussi-Gross R, Golan H, Fishlev G, et al. Hyperbaric oxygen therapy can improve post concussion syndrome years after mild traumatic brain injury: randomized prospective trial. PLoS One. 2013;8(11):e79995. doi:10.1371/journal.pone.0079995
- Chen J, Zhang F, Zhao L, et al. Hyperbaric oxygen ameliorates cognitive impairment in patients with Alzheimer’s disease and amnestic mild cognitive impairment. Alzheimers Dement (N Y). 2020;6(1):e12030. doi:10.1002/trc2.12030
- Shahid A, et al. Hyperbaric oxygen therapy (HBOT) for neurocognitive deficits following traumatic brain injury: a systematic review and meta-analysis. Ann Med Surg (Lond). 2025. doi:10.1097/MS9.0000000000003902
- Mayo Clinic. Hyperbaric oxygen therapy. Patient care and health information. mayoclinic.org
Medical Disclaimer
The content on BaricBoost.com is for informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.
Author
Seph Fontane Pennock is the founder of BaricBoost.com and Regenerated.com, a clinic directory for regenerative medicine serving 10,000+ providers across the United States. He previously built and sold PositivePsychology.com, which grew to 19 million users and became the largest evidence-based positive psychology resource on the web. Seph brings direct experience as an HBOT patient, having completed protocols at clinics across three continents while navigating mold illness, systemic inflammation, and autoimmune conditions. His treatment journey includes hyperbaric oxygen therapy, peptide protocols, NAD+ therapy, and consultations with specialists from Dubai to Cape Town to Mexico. This combination of entrepreneurial track record and lived patient experience shapes everything published on BaricBoost.com. Every article is grounded in peer-reviewed research, informed by real clinical encounters, and written for patients making high-stakes treatment decisions. Seph's focus is on bringing transparency, scientific rigor, and practical guidance to the hyperbaric oxygen therapy space.
